[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613397":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":90,"collaborators":10,"id":94,"slug":10,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":100,"sex":101,"minAge":102,"maxAge":10,"enrollmentInfo":103,"targetDuration":10,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":10,"overallStatus":109,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Xiamen Hospital of Traditional Chinese Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MNOSD patient group",null,"The NMOSD patient cohort consisted of adults (≥18 years) who met the 2021 Chinese diagnostic criteria, were AQP4-IgG seropositive, and provided informed consent.",[13],"Other: Sex hormone assay",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy control group","Age- and sex-matched healthy controls (≥18 years) who provided informed consent",[13],[19,23],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Sex hormone assay","This study will explore and validate the characteristics of sex hormone levels in MNMOSD",[9],{"type":6,"name":20,"description":24,"armGroupLabels":25,"otherNames":10},"This study will explore the comparison of sex hormone levels between a healthy control group and MNMOSD",[15],[27],{"name":28,"affiliation":5,"role":29},"Shiyong Li","STUDY_CHAIR",[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Wei Yiming","CONTACT","+8615652385796","982210496@qq.com",[37,54,64,70,80],{"facility":38,"status":10,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The First Affiliated Hospital of Xiamen university","Xiamen","Fujian","361000","China",{"type":44,"coordinates":45},"Point",[46,47],118.08187,24.47979,{"lat":47,"lon":46},[50],{"name":51,"role":33,"phone":52,"phoneExt":10,"email":53},"Jianpeng Li","+86 13860192261","806469536@qq.com",{"facility":55,"status":10,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"The Second Affiliated Hospital of Xiamen Medical College",{"type":44,"coordinates":57},[46,47],{"lat":47,"lon":46},[60],{"name":61,"role":33,"phone":62,"phoneExt":10,"email":63},"Ruiqiang Peng","+86 15880297185","hbprq@163.com",{"facility":5,"status":10,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},{"type":44,"coordinates":66},[46,47],{"lat":47,"lon":46},[69],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},{"facility":71,"status":10,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Zhongshan Hospital (Xiamen), Fudan University",{"type":44,"coordinates":73},[46,47],{"lat":47,"lon":46},[76],{"name":77,"role":33,"phone":78,"phoneExt":10,"email":79},"Guoqiang Fei","+86 13681973572","fei.guoqiang@zs-hospital.sh.cn",{"facility":81,"status":10,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Zhongshan Hospital Xiamen University",{"type":44,"coordinates":83},[46,47],{"lat":47,"lon":46},[86],{"name":87,"role":33,"phone":88,"phoneExt":10,"email":89},"Xingyu Chen","+86 136 0090 4488","2005chenxingyu@163.com",{"type":91,"investigatorFullName":92,"investigatorTitle":93,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Li Shiyong","Xiamen Traditional Chinese Medicine Hospital","100613397",false,"NCT07266051","Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)","NMOSD","Inclusion Criteria Inclusion Criteria for the NMOSD Patient Group\n\n* Aged 18 years or older, regardless of sex\n* Fulfilled the diagnostic criteria for Neuromyelitis Optica Spectrum Disorders as defined by the 2021 Chinese guidelines for the diagnosis and management of NMOSD\n* Seropositive for AQP4-IgG\n* Provided informed consent by the participant or their legal guardian\n\nInclusion Criteria for the Healthy Control Group\n\n* Aged 18 years or older, regardless of sex\n* Gender- and age-matched healthy individuals\n* Provided informed consent by the participant or their legal guardian\n\nExclusion Criteria\n\n* Diagnosis of other serious systemic diseases (e.g., malignancy)\n* Presence of severe psychiatric disorders that would preclude compliance with study procedures and\u002For follow-up assessments\n* History of infectious pathologies of the central nervous system\n* Those with severe liver and kidney function impairment or dysfunction of other vital organs\n* Patients with other conditions that do not allow participation in clinical research\n* Patients allergic to gadolinium-DPTA\n* Patients with other conditions that do not allow participation in clinical research",true,"ALL","18 Years",{"count":104,"type":105},4000,"ESTIMATED","OBSERVATIONAL","This study aims to characterize sex hormone alterations and their potential clinical significance in NMOSD patients from Southern China through comprehensive hormonal profiling.",[98],"NOT_YET_RECRUITING","2025-12-11",{"date":112,"type":113},"2025-12-18","ACTUAL",{"date":115,"type":105},"2025-12",{"date":117,"type":105},"2030-12",{"name":5,"class":6},5]